Integra LifeSciences Holdings Corporation has announced that Mark Augusti has joined Integra as CVP, President, Orthopedics and Tissue Technologies. Mr. Augusti will be responsible for the management of the company’s Spine and Extremities divisions, including strategic direction, portfolio management and evaluation of corporate development opportunities.
Background
Integra says it expects this organizational change to provide it with the focus and expertise to accelerate growth in this important area of the business while advancing the Company’s optimization goals. The aim is to enable better trade-offs to be made around resources and investments at a divisional level. The creation of the integrated Orthopedics and Tissue Technologies group will increase the effectiveness and capabilities of the combined division to fund the highest priority investments and fuel growth.
Mr. Augusti brings more than 25 years of deep knowledge and experience in medical technology management and strategic decision-making at leading international organizations. His broad leadership experience in Orthopedics, specifically Spine, Biologics, Trauma and Extremities, makes him uniquely qualified to lead Integra’s new division and strengthen its executive leadership bench.
Prior to joining Integra, Mr. Augusti served as Chief Executive Officer at Bioventus and was a member of the company’s Board of Directors. Prior to that Mr. Augusti spent nine years with Smith & Nephew in a series of leadership roles, most recently as President of Smith & Nephew’s Biologic Division, where he was appointed to lead Smith & Nephew’s new biologics initiative. He also served as Smith & Nephew’s President of the Orthopaedic Trauma & Clinical Therapies Global Business and Senior Vice President and General Manager of the Trauma business. Prior to that, he spent 13 years at GE Medical Systems, where he held various sales, marketing and strategic management roles, both in the U.S. and internationally. Mr. Augusti received his M.B.A. from UCLA Anderson School of Management, and his B.S. in Computer Science and Economics from Duke University.
Company comments
“I am pleased that Mark has become a member of our team,” said Mr. Arduini, Integra’s President and Chief Executive Officer. “With more than 25 years of experience in orthopedics, in particular, extremities and biologics, Mark brings a depth of general management experience and leadership that will be instrumental to our growth strategy.”
New incumbent comments
“I am looking forward to becoming a part of Integra’s team to lead the Orthopedics and Tissue Technologies business and advance our growth strategy forward,” said Mr. Augusti, Integra’s CVP, President, Orthopedics and Tissue Technologies. “We have an opportunity to bring a business to scale in a dynamic market and to commercialize exciting new technologies in extremities, wound care, orthobiologics and spine.”
Source: Integra Lifesciences Holdings Corporation